OL(1)p53

a 20-mer synthetic phosphorothioate oligonucleotide with a sequence complementary to p53; used in Phase I clinical trial for the treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Benner, E J: 1 article (07/2001)
2.	Bishop, M R: 1 article (07/2001)
3.	Copple, B: 1 article (07/2001)
4.	Greiner, T C: 1 article (07/2001)
5.	Iversen, P L: 1 article (07/2001)
6.	Jackson, J D: 1 article (07/2001)
7.	Joshi, S S: 1 article (07/2001)
8.	Mann, S L: 1 article (07/2001)
9.	Rao, A K: 1 article (07/2001)
10.	Sharp, J G: 1 article (07/2001)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/1994 - "Antisense oligonucleotide OL (1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia." 04/01/1996 - "In vitro incubation of acute myelogenous leukemia with OL(1)p53, a 20-mer phosphorothioate oligonucleotide complementary to p53 mRNA, results in leukemic cell death. " 10/01/1997 - "Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome." 10/01/1997 - "In preliminary studies, OL(1)p53, a 20-mer phosphorothioate oligonucleotide directed against p53 mRNA, decreased the number of acute myelogenous leukemia (AML) cells in vitro, suggesting a possible role for OL(1)p53 in purging bone marrow harvests of leukemia cells. "
2.	Hematologic Neoplasms (Hematological Malignancy) 04/01/1996 - "A phase I dose-escalating trial was conducted to determine the toxicity of OL(1)p53 following systemic administration to patients with hematologic malignancies. " 04/01/1996 - "Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies."
3.	Leukemia 10/01/1997 - "The data show that OL(1)p53 can be used safely to purge autologous bone marrow harvests from patients with leukemia." 10/01/1997 - "In preliminary studies, OL(1)p53, a 20-mer phosphorothioate oligonucleotide directed against p53 mRNA, decreased the number of acute myelogenous leukemia (AML) cells in vitro, suggesting a possible role for OL(1)p53 in purging bone marrow harvests of leukemia cells. "
4.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/01/1997 - "OL(1)p53 was then used to ex vivo purge bone marrow harvests from nine patients with either AML or myelodysplastic syndrome (MDS). " 10/01/1997 - "Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome."
5.	Lymphoma (Lymphomas) 07/01/2001 - "Corresponding to these events, the growth of WMN cells ceased after 48 hours in the concurrent presence of OL(1) p53 and Idarubicin and, the lymphoma cells were dead after 72 hours. " 07/01/2001 - "The effects of combining a phosphorothioate oligonucleotide OL(1) p53, which transiently down-regulates p53 levels, with an anthracycline, Idarubicin, on the growth of wild-type p53 WMN gene-expressing lymphoma cells was evaluated. "

Related Drugs and Biologics

1.	Oligonucleotides
2.	Antisense Oligonucleotides
3.	Messenger RNA (mRNA)
4.	Anthracyclines
5.	Idarubicin (4 Demethoxydaunorubicin)

Related Therapies and Procedures

1.	Bone Marrow Purging
2.	Autologous Transplantation